Back to News
Market Impact: 0.15
Belhaven Biopharma Initiates Pivotal Study of BBP01, a Nasal Powder Formulation of Epinephrine to Treat Anaphylaxis
Source: Newswire
Healthcare & Biotech
A randomized crossover trial in healthy participants will compare the pharmacokinetics and pharmacodynamics of intranasal epinephrine powder with an intramuscular auto-injector and manual injection. The article provides no trial results or participant count.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Why is Telix Pharmaceuticals stock rallying today?
- Why is Natera stock sliding today?
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)
- Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
- LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
- Why is Illumina stock sliding today?